Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Christopher J Leintz

Christopher J Leintz

Christopher J Leintz USA

Ronald A Rader

Ronald A Rader

Biotechnology Information Institute USA

Chang-Guo Zhan

Chang-Guo Zhan

University of Kentucky USA

Abe Hershkovitz

Abe Hershkovitz

Hershkovitz & Associates, PLLC USA

Andy Upsall

Andy Upsall

BioOutsource UK

András Guttman

András Guttman

University of Pannonia USA

Gene M. Ransom, III

Gene M. Ransom, III

University of Maryland and University of Baltimore School of Law USA

Timothy J Shea

Timothy J Shea

Sterne, Kessler, Goldstein & Fox P.L.L.C USA

Biosimilars Congress 2019

About conference

 

Biosimilars Conferences is inviting you to attend Biosimilars Congress 2019 on March 18-19, 2019 Amsterdam | Netherlands. The topic of the current year's gathering is Biosimilars & Biologics: Present Scenario & Future Prospects which will give a worldwide stage to talk of present and future of Biosimilars.

Biosimilars Congress 2019 gathering will empower us to continue plunging further into both the examination of Biosimilar change and the business necessities for associations.

The Organizing Committee is satisfied to welcome you to attend the "13th International Conference on Biosimilars and Biologics", one of its astonishing Pharmaceutical gatherings to be held in March 18-19 | 2019 in Amsterdam, Netherlands.

Our Conferences on Biosimilars joins scientists, authorities and CROs from around the world. The Biosimilars Congress 2019 experiences an exponential improvement over the coming couple of years. Various Biologics things are affecting their passage in the pharma to publicize and experiencing a striking climb in their utilization over the standard remedies.

At Biosimilars 2019 meet your planned intrigue bunches from around the world focused on getting some answers concerning Biosimilars and Biologics. This gathering would be your single most obvious opportunity to accomplish the greatest accumulation of individuals from the Biosimilars and Biologics gathering.

Biosimilars Congress 2018 gather was a hit we could get learning from two specific gathering one that surpassed desires in the deliberate and collecting end and one that surpassed desires in the business and key end.

This year’s flagship event will gather top Europe Associations, Societies, Companies, Laboratories, Global regulators, Officials, Healthcare Actors as well as Industry leaders, to foster open exchange and debate on the role of the Biosimilars and Biologics sector in “Biosimilars Congress 2019 : Present Scenario & Future Prospects”.

Why to Attend?

Biosimilars Congress 2019 gives a complete 360-degree overview on Biosimilars and Biologics: Present scenario & Future prospects. Participants will leave the conference with a wealth of new information and an expanded network of contacts.

The Biosimilar is a lucrative sector owing to recent regulatory approvals and increasing opportunities. Biosimilars and Biologics are at different stages of evolution across the globe. Developing a Biosimilars demands huge investment, technical capabilities and clinical trial expertise. In order to unlock the Biosimilars potential, the industry will entail focused strategies along the whole value chain, from optimizing the clinical development program to commercialization.

Biosimilars Conferences developments are maintaining their momentum and the 2019 Biosimilars Conferences programme delves into strategic discussions regarding:

  • Market and regulatory developments in the Europe and globally, enlightened by the perspective of healthcare professionals and patients experiences
  • Pharmacovigilance and clinical practice - what can be learned from the emerging data?
  • The impact of Biosimilars on the competitive landscape of biological products
  • Developing Biosimilars & Biobetters
  • Innovator Pharmaceutical Products of Biosimilars
  • Current Challenges and Research trends in Biosimilars & Biologics
  • Biosimilars: Pharmacovigilance and Safety
  • BCS & IVIVC Based Biowaivers
  • Biopharmaceutical
  • Biological Medicines
  • Bioequivalence Assessment
  • Developing Biosimilars & Biobetters
  • Generics and Biosimilars: Industrial Strategy
  • Globalization of Biosimilars
  • GMP, GCP, QC & R&D
  • Innovation and Technology for Biosimilar Development
  • Intellectual Property Rights
  • Novel Drug Delivery Technologies
  • Pharmacology and Drug Development
  • Plant Produced Biosimilars
  • Protein Biotherapeutics and Biosimilars
  • Regulatory Approach for Biosimilars

Learning objectives

  • Update the participants on the current knowledge including regulatory and scientific thinking
  • Deal with regulatory requirements, scientific and operational challenges
  • Exchange experiences and discuss hot topics with experts
  • Frame the current issues and create dialogue

Key Features

  • Meet Regulatory Expectations
  • Devise Strategies
  • Explore different statistical approaches to demonstrate Biosimilarity with the reference product
  • Panel Discussion and Extended Q&A Sessions
  • Open forum to discuss your most critical questions around Biosimilars & Biologics
  • National & International Speakers
  • Networking with National and International Industry stalwarts who will inspire, educate and engage in all the aspects of Biosimilars.
  • Gain insights and enhance your knowledge with Biosimilars Congress 2019.
  • Provides interaction with the world's well known CEO's and Directors of the Pharmaceutical companies.

In this limelight, Biosimilars Congress is pleased to announce the “13th International Conference on Biosimilars and Biologics” on March 18-19, 2019 in Amsterdam, Netherlands. This conference will congregate top industry stalwarts to discuss key challenges and best practices from development to launch of Biosimilars and Biologics of market existence

Join your companions the world over focused on getting some answers concerning Biologics and Biosimilars related advances, which is your single most obvious opportunity to accomplish the greatest gathering of individuals from the Biosimilars society, coordinate shows, scatter information, meet with recurring pattern and potential specialists, make a sprinkle with new research works, and get name affirmation at this Two-day event. Broadly acclaimed speakers, the most recent research, moves, and the most momentum refreshes in Biologics and Biosimilars are indications of this gathering. Provision of information on new technologies implemented in the field of Biosimilars and a sound knowledge on the Clinical Trail development.

Benefits to Attend!

Benefits to attend Biosimilars Congress 2019

  • Keynote introduction alongside connections to excite established researchers.
  • Workshop and symposiums to achieve the biggest array of members from the Pharma / Biotech people group.
  • A wide track of exhibitors to grandstand the new and rising advancements
  • Platform to worldwide speculation group to interface with partners in Pharma/Biotech area
  • Links to the political promoting assets keeping in mind the end goal to extend your business and research organize
  • Triumph of Awards, Certificates perceives your sense of duty regarding your calling to empower the incipient research.

Biosimilars 2019 Benefits:

  • Open board exchanges: Providing an open gathering with specialists from the scholarly world and business to talk about on current difficulties in Biosimilars and Biologics, where all participants can collaborate with the board took after by a Q&A session.
  • Speaker and notice introductions: Providing a stage to all academicians and industry experts to share their exploration contemplations and discoveries through a discourse or a publication introduction.
  • Editorial executive gathering: Discussing on development and advancement of open access Bioanalysis and Biomedicine International Journals and enlisting board individuals and analysts who can bolster the diary.
  • Round table gatherings: Providing a stage where industry experts meet scholastic specialists.

Business and Exhibitor Benefits:

Over 50+ organizations and international pavilions will be exhibiting at the Biosimilars 2019 conference. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The Biosimilars Congress 2019 has everything you need, all under one roof, saving you both time and money.   It is the event you cannot afford to miss!

Market Analysis

With 15 years of experience-sharing on scientific assessment, regulatory approval and the introduction of Biosimilars and Biologics in clinical practice, this conference will take us to new uncharted waters in preparing for this new era.

Biosimilars and Biologics have been well versed in the therapeutic areas where they have been used (e.g. rheumatology, gastroenterology) with positive benefits on access to treatment, and therefore on patient outcomes. They are about to enter cancer patient pathways where the anticipated benefits will represent a unique opportunity for re-investment in needed healthcare products and services.

Market and regulatory developments in the Europe and globally, enlightened by the perspective of healthcare professionals’ and patients’ experiences

The impact of Biosimilars and Biologics on the competitive landscape of biological products is huge. The Biosimilar is a lucrative sector owing to recent regulatory approvals and increasing opportunities. Biosimilars are at different stages of evolution across the globe. Developing a Biosimilars demands huge investment, technical capabilities and clinical trial expertise. In order to unlock the Biosimilars potential, the industry will entail focused strategies along the whole value chain, from optimizing the clinical development program to commercialization.

Biosimilar Market in Europe:

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as Biosimilars in Europe. Patent expiry of key product classes and a growing emphasis on cost-effectiveness is making governments switch to affordable alternatives.

The EMA approved four additional Biosimilars in 2016, including three Biosimilars in two new product classes: a biosimilar of Amgen’s Enbrel (etanercept) and two Biosimilars of Sanofi’s Clexane (enoxaparin sodium).  Etanercept is a fusion protein used to treat a variety of autoimmune disorders and enoxaparin sodium is a low-molecular-weight heparin indicated for preventing blood clots.  These additional approvals bring the total of currently authorized Biosimilars in Europe to 22 and the product classes to eight

It was estimated that in 2015, Europe accounted for the largest market share of the global Biosimilars market, followed by Asia Pacific. Here is thus a tremendous opportunity for Biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

 About 30 companies are actively developing Biosimilars and Biologics are researching on the Biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the Biosimilars market as a number of Biologic drugs are going to lose their exclusivity.

Biosimilars Market in Asia Pacific:

Asia-Pacific is the fastest growing market for Biosimilars because of low manufacturing expenses, availability of skilled and cheap labor, lenient regulations laid by governments. In fact, governments are encouraging the use of Biosimilars. For example, the government of India provides various necessary and regulatory procedures for the usage of Biosimilars products.

Asia-Pacific Biosimilars Market was worth $0.78 billion in 2016 and estimated to be growing at a CAGR of 39%, to reach $4.05 billion by 2021.

Based on geography the Asia-Pacific market is segmented into various regions namely Japan, China, India and Australia.

India and China are estimated to grow the fastest. Other countries such as South Korea are also expected to record high growth over the next five years. India is one of the largest hubs for the biosimilar industry and observes a presence of over 30 leading firms that operate in the development of Biosimilars, some of which include Dr. Reddy’s Laboratories, Wockhardt, Lupin, Cipla, Avesthagen, Biocon, and Zydus Cadilla.

Global Biosimilars Market:

While the U.S. has approved only one Biosimilar therapeutic; Japan, Australia and Europe have approved six, eight and 19 Biosimilars respectively. Already, Biosimilars have an exemplary safety track record in the E.U., Japan, and Canada where Biosimilars are regularly competing against Biologics for nearly seven years. The E.U. was the first geographic market to develop the process of authorization of Biosimilars, setting an example for many other developing markets to follow suit. As of 2015, the E.U. has approved 19 Biosimilars, out of 21 submissions, mostly for three reference biologics such as Somatropin, Epoetin alfa and Filgrastim.

Biosimilars generated revenues of $1.1 million in 2007 and gradually rose to $86.9 million in 2014. During this period, the market penetration of Biosimilars in Europe and emerging markets was only about 8%. The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.

Conclusion: Like most other markets, a competitive Biologics market can offer benefits to consumers by lowering prices and enhancing quality. In addition, Biosimilars have an unblemished safety track record in the E.U., where Biosimilars have been competing against biologics since 2006. Biosimilars have also proved to have a notable impact on drug prices. In the E.U., where Biosimilars are already competing with biologics, Biosimilars are sold at a 30% discount compared to branded biologic drugs.

Though Biosimilars industry faces many challenges like Patent and Legal Issues, Production Bottlenecks, Pricing Issue, Regulatory issues and lack of awareness.

In spite of the approval of 21 Biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics. However Bisimilars industry seems to have a bright future as an alternative to patent Biologics.

Over two days, participants will dive into a dynamic programme – a crossroads between technical, scientific, market discussions and the overarching healthcare policy agenda on Biosimilars and Biologics.

Sessions and Tracks

Track-1: Developing Biosimilars & Biobetters

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (Biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

Sub Tracks:

  1. Key Aspects in Technical Development
  2. Analysis of the Biosimilar Development Pipeline
  3. Legal Issues and Implementation of the BPCI Act

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-2: Intellectual Property Rights

The safeguarding of product trade secret, its formulations and other process parameters by law is usually covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance in the field of Biologics and Biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. Currently, the US provides 12 years of exclusivity for new biological products under the Biologics Price Competition and Innovation Act (BPCIA).The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law. Eight years of exclusivity would keep biologic medicines out of the hands of many who need them. Prices frequently exceed $100,000.

Sub Tracks:

  1. Pharma patent scenario
  2. Criteria for patentability and patent claims
  3. Critical research issues
  4. Patentable subject matter
  5. Recent patent disputes and litigations

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-3: Innovative Approaches for Biosimilars

A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise Biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

Sub Tracks:

  1. Biosimilar Product Reimbursement and Pricing
  2. Biosimilar Regulatory Updates and Legal Implications
  3. Biosimilar Market Access and Commercialization

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-4: Regulatory Advances in Biosimilars

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6 percent with one generic competitor, but jumps to 48 percent with two generic competitors, 56 percent with three, 61 percent with four and 67 percent with five generic producers in a market. Within two years of the expiration of the patent for the popular drug Zantac in mid-1997, generic versions accounted for 90 percent of the treatment’s total sales, and the price for patients was about 10 percent of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners received EMEA approval for the first European Biogenerics, two products containing human growth hormone.

Sub Tracks:

  1. Biosimilars regulation
  2. BLA filing for Biosimilars
  3. Regulatory prospects of BRIC countries
  4. Aparadigm of traditional generics to Biosimilars
  5. Biowaiver approval for Biosimilars
  6. Generic Biosimilars
  7. Regulatory Prospects in BRIC countries

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-5: Legal Issues and BPCI Act

The legal issues pertaining to the follow-on-Biologics and Biosimilars are one of the most aspects that require an open discussion. Before the actual advent of Biosimilars to the market legal issues have risen in numbers in their developmental stages. Renowned organizations have filed cases against each other two claim their rights and for other legal allegations related to the products. This track is dedicated to discussion of all such cases which has been argued in the court of law. By 2002, the FDA had approved 36 new Biologics, followed by 37 more in 2003, another 40 in 2004 and 39 more in 2005. By 2006, the leading category of biologic treatment, the red blood cell enhancer recombinant erythropoietin (EPO), generated $14 billion in sales revenues, or 40 percent more than the best-selling traditional pharmaceutical, Lipitor. More than 300 therapeutic antibodies currently are in clinical development and trials, compared to just 13 that already are widely available due to legal issues.

Sub Tracks:

  1. Implementation of the BPCI Act
  2. Patent protection and infringement issues
  3. Patent negotiation and litigation phase
  4. Market exclusivities

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-6: Current Agency Expectations for Approval for Biosimilars

Biosimilars are a relatively new subset of biopharmaceuticals, with the biotechnology industry finally maturing such that off-patent generic-type products increasingly will be entering major markets. So far, more than 20 Biosimilars for a limited number of reference products have been approved in major markets, primarily the European Union. Only two products have been formally approved as Biosimilars in the United States. The parent field of biopharmaceuticals itself continues to exhibit a poor supporting infrastructure of information resources. Those biopharmaceutical and biosimilar information resources that do exist generally are limited in number, diversity, and sophistication.

Sub Tracks

  1. Drug safety of Biosimilars products
  2. Regulatory aspects
  3. Regulatory affairs and IPR of Biosimilars products

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-7: Novel Drug Delivery Technologies

Biosimilar Engineers and their outsourcing accomplices must know about the picked nation's administrative scene, and have broad information of any current Biosimilar endorsement pathway and the most recent administrative organization rules. Furnishing administrative experts with endorsements of investigation (CoA) for a U.S. - advertised comparator could challenge. As opposed to European practice, U.S. makers tend not to make CoAs accessible to parties required in the production network or bolster the improvement of a contender by discharging CoAs for clumps acquired for clinical trials. Giving family proclamations to the reference item more often than not is acknowledged as an option.

Sub Tracks:

  1. Product Similarity for Biosimilars & Analytical Challenges
  2. Role of Medical Affairs in Biosimilars
  3. Regulatory strategy for generics and Biosimilars

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-8: USFDA Approved Biosimilars

The European regulatory authorities led with a specially adapted approval procedure to authorize subsequent versions of previously approved Biologics, termed "similar biological medicinal products", or Biosimilars. This procedure is based on a thorough demonstration of "comparability" of the "similar" product to an existing approved product. In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve Biosimilars to those Biologics originally approved through the PHS Act pathway. The FDA gained the authority to approve Biosimilars (including interchangeable that are substitutable with their reference product) as part of the Patient Protection and Affordable Care Act signed by President Obama on March 23, 2010.

Sub Tracks:

  1. Biosimilar and Interchangeable Products
  2. Biosimilar Development, Review, and Approval
  3. Prescribing Biosimilar and Interchangeable Products
  4. Biosimilar Product Information
  5. Industry Information and Guidance

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-9: Consequences of Brexit on Biosimilars

With Europe that paved way to the uptake of Biosimilars over a decade ago, the consequences of Brexit would be potentially harder on UK. Presently UK is no more bound to follow the guidelines of EMA. Also research grants from Innovative Medicines Initiative and Horizon 2020 would no more be available to UK. All the same, EMA has its headquarters in London, UK. The thus arising complications would definitely have certain consequences on the Biosimilars scenario in UK and EU.

Sub Tracks:

  1. Brexit- Pros and Cons to European pharma market
  2. Post Brexit changes in Biosimilars regulation in UK
  3. Fate of Biosimilars clinical trials in UK
  4. Research funding from European organizations to UK based research laboratories

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-10: Biosimilars Market Strategy

Effective management of a current good manufacturing practice (GMP) facility requires a strict eye on all those factors. This also includes Bioanalytical methods, Formulation, Bioassay for comparability and potency testing, GMP protein analysis, LC/MS analysis for discovery, preclinical, and clinical programs. Analysis of Biosimilars and Biologics forms to be one of the most important aspects towards the Biologics and Biosimilar development process. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry. The market for Biosimilars follow-on-Biologics is expected to grow at an exponential rate for next decade with the expiry of most patented drugs by 2020.The market in the APAC region for Biosimilars reached $605 million in 2010 and $683 million in 2011. The market is expected to reach $1.1 billion by 2016, a CAGR of 10.3%. The market in the United States for Biosimilars reached $507 million in 2010 and $1.1 billion in 2011. The market is expected to reach $1.3 billion by 2016, a CAGR of 4.1%.

SubTracks:

  1. Biosimilar bioanalytical methods
  2. Biosimilar Formulation
  3. Bioassay for comparability and Potency Testing
  4. Biosimilar GMP protein analysis
  5. Biosimilar lc/ms analysis for discovery, preclinical, and clinical programs
  6. Biosimilar Electrophoresis
  7. Biosimilar multimodal techniques
  8. Biosimilars companies

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-11: Emerging Biosimilars in Therapeutics

Biosimilars Market is experiencing a growth at an exponential rate. Presently around 700 Biologics are making progress in the research pipelines of nearly 250 Biopharma companies. Biosimilar insulins have already started revolutionizing the future drug development in the realm of diabetology. Biosimilars of Adalimumab, Etanercept, Rituximab, Peg-Filgrastim, Trastuzumab are expected to hit the market soon. Biosimilar of Humatrope, biosimilar of Eprex, biosimilar of Neupogen, biosimilar of Remicade have already been enjoying a greater market share in Europe than the reference product itself. The proportion of different Biosimilars that reached market are Low Molecular Weight Heparins 44%, Epoetins 19%, HGH 11%, G-CSFs 7%, Interferons 6%, Insulins 5%, Others 8%.

SubTracks:

  1. Biologics in cancer
  2. Biologics for psoriasis
  3. Biosimilar monoclonal antibodies
  4. Recombinant therapeutic proteins
  5. Insulin Biosimilars
  6. Biologics in autoimmune disease

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-12: Challenges in Biosimilars

The generic version of Biologicals- “Biosimilars” is the new buzz word in the world of pharmaceutical industry. Biosimilars are highly similar to their licensed reference product not withstanding minor differences as excipients in the formulation; also there are no remarkable differences between the Biologicals and the reference product in terms of safety, purity, and potency. However, there are certain challenges in way of its development and receiving a green signal for launching into the market. Newer Biologics also are targeting widespread diseases, with profound implications: a drug that costs $20,000 per year that is useful for 1 person in 100,000 has much less effect on a health plan’s cost structure than a $5,000-per-year drug that is useful for 1 in 100 people.

SubTracks:

  1. Current concepts of drugs and Biologics
  2. Unique considerations for Biologics
  3. Early clinical development essentials
  4. Late clinical development essentials
  5. Drug safety essentials
  6. Cancer Therapeutics
  7. Comparability for Biologics
  8. Quality by Design for Biologics and Biosimilars

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-13: Chemical and Analytical Strategies for Biosimilars

Management of cGMP facility calls for a strict monitoring all factors including analytical strategies, formulation procedures, packaging etc. For biologic products establishing comparability and interchangeability is a big hurdle. For this purpose employment of suitable analytical approach, bioassay, protein analysis, potency testing, safety assurances are highly important. LC/MS analysis for biologic products, characterization of Biologics, peptide mapping, Isoelectric Focusing and Capillary Isoelectric Focusing, SDS-PAGE, Thermal Analysis, Particulate Matter Analysis, Thermogravimetric Analysis are some methods commonly used for analysis of Biologics and Biosimilars products. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry.

While small changes in these parameters can impact the various chemical permutations for a given biotherapeutic, innovators can, under certain circumstances, change the host cell, fermentation process, purification process, and even manufacturing site, but the product can be validated without undertaking a complete new product development review.

SubTracks:

  1. Biosimilars multimodal techniques
  2. Biosimilars bioanalytical methods
  3. Bioassay for comparability and potency testing
  4. Biosimilars LC/MS analysis for discovery, preclinical and clinical programs
  5. Biosimilars GMP protein analysis
  6. Biosimilars electrophoresis

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-14: Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug. Of all attempts towards developing a follow on Biologics or a biosimilar drug the main detection point stands at the Bioequivalence Assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable Biologics or Biosimilars.

Sub Tracks:

  1. Strategies for the bioequivalence assessment of topical dosage forms
  2. Bioequivalence assessment of respiratory dosage forms
  3. Bioequivalence approaches for transdermal dosage forms
  4. Evaluation of highly variable drugs and drug products

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-15: Biological Medicines

Biological Medicine works with the biology of the body and its natural healing capabilities as well as the spiritual, emotional and physical aspects of disease. Disease means that the body’s regulation is not working properly and needs to be brought back into its natural dynamic state where the immune system is in full regulation.  It therefore looks for root causes for the presenting symptoms of disease the underlying factors causing a person to present with a certain illness.  These root causes may consist of several factors which have built up over time and can include; diet, food allergies, intestinal disturbances, family history, stress, environmental factors, heavy metals, dental problems, hyperacidity, trauma, exposure to bacteria or viruses or electromagnetic disturbances.

Sub Tracks:

  1. Advances in Biological products
  2. Biological drugs
  3. Generic Biological drugs
  4. Biotechnology medicinal products for different drugs
  5. Future of next generation Biosimilars
  6. Biopharmaceuticals development

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-16: Biosimilars Approval to Biogenerics in Clinical Practice

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on Biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a Biosimilars. According to current literature, the following points on Biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of Biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on Biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in Biosimilars.

SubTracks:

  1. Biotechnologic drug
  2. Monoclonal antibody
  3. Fusion protein
  4. Biologic drug
  5. Anti–tumor necrosis factor

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-17: Biopharmaceutical

Biopharmaceutical are also called medical product these Biopharmaceuticals includes blood, blood components, gene therapy, Recombinant therapeutic protein. Biopharmaceutical informatics is used in information technology, molecular modeling and biologic drug development. Development of databases containing the experimental data on biophysical stability, safety along with molecular sequence

Sub Tracks:

  1. Applications of computation in Biologic drug development
  2. Protein sequence-structural contexts and degradation reaction mechanisms
  3. Creation of databases and data mining
  4. Pre-clinical immunogenicity risk assessment of Biotherapeutics
  5. Monoclonal antibodies (Various)
  6. Blood components
  7. Vaccines
  8. Biopharmaceutical Research

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-18: BCS & IVIVC Based Biowaivers

The objective of this track is to suggest the Biowaivers potential of Biopharmaceutical classification system which is known to increase the solubility, dissolution, oral absorption of water insoluble drugs. Biopharmaceutics Classification System and Invitro and Invivo classification discusses about ADME pathways of different drugs. This track also includes BCS biowaivers, in vitro diffusion cells for dissolution testing in formulation development, in vitro preclinical ADME/BCS testing. Until in vitro in vivo correlation achieves the required degree, the Biosimilar drug will not be able to meet the needs of the original drug candidate. Hence the proportion of BCS and IVIVC based biowaivers are fairly low ~0.5-1% of total pharmaceutical products.

Sub Tracks:

  1. BCS biowaivers
  2. Preclinical and clinical testing for oral drug delivery
  3. Waiver for In vivo Bioavailability or Bioequivalence
  4. Consideration of Biowaiver extensions for BCS class III drugs
  5. In vitro diffusion cells for dissolution testing in formulation development
  6. Dissolution testing in drug formulation
  7. In vitro preclinical ADME/BCS testing
  8. In vitro drug product research

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-19: Pharmacovigilance Challenges and Safety

Biosimilar guidelines for Pharmacovigilance practice and Pharmacoepidemiology are the points that shall be laid emphasis in this session. U.S. average annual spending growth from 2002 to 2007 was 16% for Biologics, compared with 3.7% for drugs. In same proportion Pharmacovigilance for Biosimilars has been comparatively more than other pharmaceutical products. Biosimilars are interlinked with FDA activities that have as of now been declared to incorporate upgraded following and follow-up of post market issues, arranged changes in AERS, and pilots of new post advertise medicate observing systems. Current difficulties in Pharmacovigilance, adverse medication responses with pharmaceutical items, Biosimilar rules for Pharmacovigilance practice and pharmacoepidemiology are the focuses that should be laid accentuation in this session.

SubTracks:

  1. Current problems in Pharmacovigilance
  2. Adverse drug reactions with Pharmaceutical products
  3. Detection and evaluation of drug safety signals
  4. Improve Pharmacovigilance through Patient and Provider Education
  5. Regulatory updates and key drivers for registration approvals in US, EU and China
  6. Regulatory requirement for Biosimilar IND filing in the US
  7. Role of Pharma industries in the improvement of Pharmacovigilance system

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-20: Generic Biosimilars: Industrial Strategy

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs and Analysis of key therapeutic areas and leading generic drugs  pufecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, Pharmaceutical Industry  opportunities, future road map, Following key trends, market drivers, challenges, Analysis of key therapeutic areas and leading generic trends ,value chain, ecosystem player profiles and strategies and  Regulatory landscape of global trends  throughout the globe The report also presents market size forecasts for generic drugs from 2017 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Sub Tracks:

  1. Clinical development strategies for Biosimilars
  2. Advances in Biosimilar Production & Technologies
  3. Scale Up of Biosimilars
  4. Business Development in biosimilar
  5. Major market trends & Featured regional market trends

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-21: Formulation Strategies for Follow-on Biologics

For this rapidly growing industry sector, little consensus or authoritative information is available yet regarding how and where biosimilar products will be produced. The future of their manufacturing is still up in the air. Much discussion among experts has focused on a dramatic up-tick in Contract Manufacturing Organizations (CMOs) involvement with process development projects and clinical-scale manufacturing for Biosimilars. None have really set up commercial-scale projects (yet), however. Many such companies are publicly discussing large-scale partnerships for production in India and elsewhere in Asia. On the other hand, some Biosimilars sponsors are establishing relationships with smaller biotech CMOs that have demonstrated expertise in efficiency or lower-cost business models

Sub Tracks

  1. Multiproduct or dedicated single product plants
  2. Major markets or developing countries
  3. Single-use, stainless steel or hybrid
  4. Continuous bioprocessing

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-22: Pharmacology and Drug Development

Pharmacology is the branch of solution and science worried with the investigation of medication action where a medication can be comprehensively characterized as any man-made, characteristic, or endogenous (from inside body) particle which applies a biochemical and additionally physiological impact on the cell, tissue, organ, or living being (once in a while the word Pharmacon is utilized as a term to envelop these endogenous and exogenous bioactive species). Sedate improvement is the way toward conveying another pharmaceutical medication to the market once a lead compound has been distinguished through the procedure of medication revelation. It incorporates pre-clinical research on microorganisms and creatures, petitioning for administrative status, for example, by means of the United States Food and Drug Administration for an investigational new generic medication to start clinical trials on people, and may incorporate the progression of acquiring administrative endorsement with another medication application to showcase the medications and Increase Global Pharma Market

Sub Tracks:

  1. Clinical pharmacology and Drug addictions
  2. Characterization of biologically active compounds
  3. Recent advancements in research and developments
  4. Recent advances in computer aided drug design
  5. Novel Approaches in drug discovery

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-23: Globalization of Biosimilars

Globalization of Biosimilars is about the generic drugs impact on Global Biosimilar market, Cost and risk management, adopting innovative mechanisms such as risk-sharing arrangement, European market for Biosimilars. A growing global market for Biosimilars is gaining momentum in response to the expiration of patents for a number of key Biologics and consumer demand to reduce treatment costs. Thus, according to Research and Markets, the global biosimilar market, valued at $2 billion in 2012 is projected to reach $19.4 billion by 2018.

Sub Tracks:

  1. Global impact of Biosimilars over generics
  2. Economic aspect towards Biosimilars
  3. Biosimilars in global market
  4. Investment and returns on Biosimilars
  5. Cost and risk management
  6. Adopting innovative mechanisms such as risk-sharing arrangement
  7. European market for Biosimilars
  8. Global P&R models for the Biosimilars and generics market

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-24: Protein Biotherapeutics and Biosimilars

Biotherapeutics more often than not alludes to helpful materials created utilizing organic means, including recombinant DNA innovation. Biotherapeutics are fundamentally operators, used to treat and maintain a strategic distance from human malady by interrelating with the microbial environment of the host. Biotherapeutics can target particular particles inside the human body, and have a decent reputation with patient wellbeing. Fabricating biotherapeutics is mind boggling, as they are bigger mixes in both size and structure, and can be touchy to ecological conditions.

Sub Tracks:

  1. Advancements in Biotherapeutics
  2. Biotech and Biosimilar Products
  3. Antibody based therapeutics
  4. Therapeutic Antibodies and Fc Fusion Proteins

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Track-25: Plant Produced Biosimilars

Biosimilar products are also produced from plants. Plants are the richest store house of diverse class of phytochemicals. Production of Biosimilar products in tobacco plants is on the verge of completion of the first step in their research. These also includes Transgenic plants, Post translational genetics, Fermentation culture, Molecular farming. For biosimilar manufacturers this session has the potential to bring up new avenues in their product range. Pharmacognosy researchers would find this track highly interesting and informative towards their research work. Proportion of plant produced Biosimilars are comparably low. However, an increased level of plant sourced Biologics ~25% is owned to be seen in the market. Especially Biologics derived from the plant sources are expected to occupy about more than 20% of all Biologics.

Sub Tracks:

  1. Transgenic plants
  2. Post translational genetics
  3. Fermentation culture
  4. Molecular farming

Suggested Conferences: Biosimilars Conferences | Biosimilars Congress | Top Biosimilar Conferences | Biosimilars Conferences 2019 | Biosimilar Conferences Europe | Biosimilars Conferences Netherlands | Biosimilars 2019 | European Biosimilars 2019

Who Will Attend?

Target Audience:

  • Executives, CEO's of Industries & Organizations
  • Business Development Managers
  • Boss Scientific Officers
  • Research and development Researchers from Biosimilars and Biologics Industries
  • Educators, Associate Professors, Assistant Professors
  • PhD Scholars
  • Patent Attorneys
  • Protected innovation Attorneys
  • Speculation Analysts
  • Affiliation, Association presidents and experts
  • Honorable laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Programming improvement organizations
  • Research Institutes and individuals
  • Inventory network organizations
  • Assembling Companies
  • CRO (Contract Research Organization) and DATA administration Companies
  • Preparing Institutes
  • Business Entrepreneurs

Few Global Universities for Biosimilars:

  • University of California, USA
  • North Carolina State University, USA
  • University of London, UK
  • Biotechnology Information Institute, USA
  • University of Toronto, Canada
  • Biotechnology Information Institute, USA
  • USC Keck School of Medicine, USA
  • University of La Sabana, Colombia
  • University of Pannonia, USA
  • USC Keck School of Medicine, USA
  • Touro College of Pharmacy, USA

Global Societies and Associations in Europe:

  • Medicines for Europe 
  • British Biosimilars Association (BBA) 
  • European Medicines Agency
  • European Association of Hospital Pharmacists
  • International generic and Biosimilar Medicines Association (IGBA)
  • Nanotechnology Industries Association
  • Royal Microscopical Society
  • Royal Society - Nanotechnology and Nanoscience
  • British Society for Nanomedicine
  • Belgian Society of Pharmaceutical Sciences (BGFW)
  • European Federation for Pharmaceutical Sciences (EUFEPS)
  • Italian Society for Pharmaceutical Sciences (SISF)
  • Association of the British Pharmaceutical Industry (ABPI)
  • A Division of the Association for Accessibility medicines (DAAM)
  • European Biopharmaceutical Trade Association
  • Biosimilars - Generic Pharmaceutical Association
  • European Generic Medicines Association.

Global Societies and Associations in the USA:

  • The Biosimilars Council
  • Association for Accessible Medicines
  • Biosimilars Resource Center (BRC) 
  • American Academy of Nanomedicine
  • American Nano Society
  • American Society for Nanomedicine
  • Canadian Society for Pharmaceutical Sciences (CSPS)
  • Pharmaceutical Manufacturers Association of Canada (PMAC)
  • American Association of Pharmacy Technicians (AAPT),
  • American Society of Health-System Pharmacists (ASHYP)
  • Canadian Society of Intestinal research (CSIR)                                                                                                                                                        

Global Societies and Associations in Asia:

  • National Center for Nanoscience and Technology
  • Indian Society for Nanomedicine
  • Nano Technology Research Association
  • Indian Society of Nanomedicine
  • The Pharmaceutical Society of Australia (PSA)
  • Austrian Pharmaceutical Society (APS)
  • Korean Research-based Pharmaceutical Industry Association (KRPIA)
  • Kuwait Pharmaceutical Association (KPA)

Past Conference Report

Biosimilars-euro 2017

Conference Series hosted the 7th European Biosimilars Congress at Novotel Munchen City Arnulfpark Munich, Germany during May 15-16, 2017.The conference was designed around the theme of “The developmental strategies and uptake of biosimilars through a decade in Europe” and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering. Moreover, the networking sessions laid the foundation for some time worthy collaborations between many start-up and big industries. The post conference networking lunch session witnessed a number of B2B meetings that are turning up to be mutually beneficial to both the organizations who had gone in for the business meetings.

Euro Biosimilars 2017 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Biologics and Biosimilars. This congress not only brought forward the latest developments in the field but also provided solutions to the numerous challenges encountered in developing a biosimilar.

Conference Series would like to convey a warm gratitude to all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation in Euro Biosimilars 2017.

  • Christoph Volpers, Michalski & Hüttermann, Germany
  • Arthur G Cook, ZS Associates, USA
  • Tim Demuth, Sandoz Pharmaceuticals GmbH, Germany
  • Rosa Helena Bustos, University of La Sabana, Colombia
  • Ulrike Konrad, Protagen Protein Services , Germany
  • Stanley Seung Suh Hong, Celltrion Healthcare Co. Ltd., South Korea
  • Ulrich Storz, Michalski Huttermann & Partner, Germany

We on behalf of the conference specially thank the exhibitors for their participation in the congress and also the media partners for their wonderful marketing of the event. Conference Series also took the privilege of felicitating Euro Biosimilars 2017 Organizing Committee, Keynote Speakers and Chair whose support made conference a great success.

With the enormous feedback from the participants and supporters of Euro Biosimilars 2017, we are glad to announce 13thInternational Conference on Biosimilars and Biologics  during March 18-19, 2019 Amsterdam | Netherlands

                            See you next year at Amsterdam | Netherlands

For More details visit:  https://biosimilars.annualcongress.com/


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date March 18-19, 2019

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Supported By

Journal of Bioequivalence & Bioavailability Journal of Bioanalysis & Biomedicine Journal of Pharmacovigilance Advances in Pharmacoepidemiology and Drug Safety

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos

Keytopics

  • Abbreviated Clinical Trial Designs
  • Analytical Strategies For Biosimilars
  • BCS Based Biowaivers
  • Bio Similar Innovative Devices
  • Bioequivalence Assessment
  • Biological Licenses
  • Biosimilar Companies
  • Biosimilar Cost Analysis
  • Biosimilar Manufacturer Strategies
  • Biosimilar Market
  • Biosimilar Medicines
  • Biosimilar Product Development
  • Biosimilars And Biologics
  • Biosimilars And Their Social Repercussions
  • Biosimilars Approved In Europe
  • Biosimilars Approved In US
  • Biosimilars Economic Predictions
  • Biosimilars In Developing Countries
  • Biosimilars Manufacturing Process
  • Biosimilars Research Pipeline
  • Challenges In Biosimilars Pharmacovigilance
  • Clinical Development Of Biosimilars
  • Commercial Landscape In Biosimilars
  • Comparison Of Biologic Drug Prices
  • Consequences Of Brexit On Biosimilars
  • Current Challenges In Developing Biosimilars
  • Differences Between Biosimilars And Generic Drugs
  • Emerging Biosimilars In Therapeutics
  • Fingerprinting Analysis
  • Future Of Biosimilars
  • Globalization Of Biosimilars
  • Health Technology Assesment Of Biosimilars
  • Innovative Approach For Biosimilars
  • Intellectual Property Rights
  • Interchangeability Of Biosimilars
  • Investigator Initiated Biosimilar Research
  • IVIVC Based Biowaivers
  • Laws On Biologics Regulation
  • Legal Issues And BPCI Act
  • Market Analysis Of Biosimilars
  • Need For Biosimilars
  • New Pathway For Biosimilars
  • Outlook On Biosimilars
  • Patient Safety In Biosimilars
  • Quality Considerations For Biosimilars Biosimilars
  • Reimbursement And Coding In Biosimilars
  • Stability Of Biosimilars
  • Substitution Of Biosimilars
  • The Savings Potential Of Biosimilars
  • Therapeutic Efficiency Of Biosimilars
  • What Are MAbs Biosimilars?
  • What Is A Biologic Medicine?
  • What Is A Biosimilar Medicine?
  • Worldwide Regulatory Status Of Biosimilars